Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares
(NQ:
KNSA
)
41.51
+0.52 (+1.27%)
Streaming Delayed Price
Updated: 12:10 PM EST, Dec 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares
< Previous
1
2
3
4
Next >
Kiniksa (KNSA) Q3 2025 Earnings Call Transcript
↗
November 27, 2025
Kiniksa (KNSA) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Combines Technical Strength and Fundamental Growth Momentum
↗
November 20, 2025
KNSA stock shows strong technical momentum per the Minervini Trend Template and impressive fundamental growth with 421% EPS growth.
Via
Chartmill
Earnings Scheduled For October 28, 2025
↗
October 28, 2025
Via
Benzinga
What to Expect from Kiniksa Pharmaceuticals's Earnings
↗
October 27, 2025
Via
Benzinga
5 Analysts Have This To Say About Kiniksa Pharmaceuticals
↗
October 17, 2025
Via
Benzinga
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Identified by High Growth Momentum and Minervini Trend Screen
↗
October 08, 2025
Kiniksa Pharma (KNSA) is a high-growth momentum stock in a strong technical uptrend, with surging earnings and sales supporting its price advance.
Via
Chartmill
Earnings Scheduled For July 29, 2025
↗
July 29, 2025
Via
Benzinga
Earnings Preview: Kiniksa Pharmaceuticals
↗
July 28, 2025
Via
Benzinga
Earnings Scheduled For April 29, 2025
↗
April 29, 2025
Via
Benzinga
Earnings Scheduled For February 25, 2025
↗
February 25, 2025
Via
Benzinga
What Analysts Are Saying About Kiniksa Pharmaceuticals Stock
↗
September 29, 2025
4 analysts have expressed a variety of opinions on Kiniksa Pharmaceuticals (NASDAQ: KNSA) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Via
Benzinga
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Shows High-Growth Momentum and Strong Technical Setup
↗
September 24, 2025
Kiniksa Pharmaceuticals (KNSA) shows explosive EPS growth of 483% and strong technicals, trading near 52-week highs in a consolidation pattern that suggests a potential breakout.
Via
Chartmill
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Emerges as an Affordable Growth Opportunity
↗
September 22, 2025
Kiniksa Pharmaceuticals (KNSA) offers strong growth potential at a reasonable valuation. With 125% EPS growth, no debt, and a forward P/E of 21.47, it's a compelling affordable growth stock.
Via
Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Emerges as a Top Affordable Growth Candidate
↗
September 01, 2025
Kiniksa Pharma (KNSA) is a strong affordable growth stock with impressive revenue & EPS growth, a reasonable valuation, and a solid debt-free balance sheet.
Via
Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Exhibits High Growth Momentum and Technical Breakout Potential
↗
August 25, 2025
Kiniksa Pharma (KNSA) shows strong earnings growth and a bullish technical setup, making it a high-growth momentum stock to watch for a potential breakout.
Via
Chartmill
KINIKSA PHARMACEUTICALS INTE (NASDAQ:KNSA): A Strong Growth Stock with a Positive Technical Breakout
↗
August 22, 2025
Kiniksa Pharma (KNSA) is a strong growth stock with 125% EPS growth, a debt-free balance sheet, and a bullish technical breakout pattern.
Via
Chartmill
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) – An Affordable Growth Stock with Strong Fundamentals and Fair Valuation
↗
August 08, 2025
Affordable Growth investing targets stocks like Kiniksa Pharmaceuticals (KNSA), balancing strong revenue/earnings growth with fair valuations and financial health. KNSA shows high growth (8/10), solid...
Via
Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Aligns with Minervini’s Trend Model as a Strong Momentum Pick
↗
August 05, 2025
Kiniksa Pharmaceuticals (KNSA) aligns with Minervini’s Trend Model, showing strong technicals, rapid earnings growth, and upward momentum—ideal for growth investors.
Via
Chartmill
Why CommScope Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
↗
August 04, 2025
Via
Benzinga
Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter?
↗
August 04, 2025
The upgraded score means Gilead is now outperforming 96% of all stocks in terms of the most important stock-picking criteria.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Friday's After-Market Session
↗
July 25, 2025
Via
Benzinga
Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth
↗
July 02, 2025
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
↗
May 05, 2025
Via
Benzinga
Pony AI, Hims & Hers And Frontdoor Are Among Top 11 Mid-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
↗
May 04, 2025
Top performers last week: PONY, HIMS, ODD, MTSR, CGON, KNSA, KC, FTDR, ATI, PRDO, and IRTC. Have you invested in them?
Via
Benzinga
Topics
Artificial Intelligence
These stocks are gapping in today's session
↗
April 29, 2025
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Via
Chartmill
Honeywell Posts Better-Than-Expected Q1 Earnings, Joins Crown Holdings, Noble, Crane And Other Big Stocks Moving Higher On Tuesday
↗
April 29, 2025
Via
Benzinga
Examining the Future: Kiniksa Pharmaceuticals's Earnings Outlook
↗
April 28, 2025
Via
Benzinga
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
↗
March 14, 2025
Via
The Motley Fool
Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst
↗
March 06, 2025
Kiniksa shifts focus to cardiovascular indications, halts abiprubart in Sjögren's, ends its AstraZeneca deal, and advances KPL-387 for recurrent pericarditis.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
January 30, 2025
Via
Benzinga
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today